Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma
Biochemical Genetics · 2025
DOI: 10.1007/s10528-024-10697-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biochemical Genetics, 2025. Verfasst von Shengqiang Huang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.420, Fuma Road, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Tumor Microenvironment, Immunogenic Cell Death, Biomarkers, Tumor. Die Arbeit nennt 45 Literaturangaben. Gefördert von: Fujian Provincial Health Technology Project, Natural Science Foundation of Fujian Province, Joint Funds for the Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
Current literatures suggest a growing body of evidence highlighting the pivotal role of Immunogenic Cell Death (ICD) in multiple tumor types. Nevertheless, the potential and mechanisms of ICD in diffuse large B-cell lymphoma (DLBCL) remain inadequately studied. To address this gap, our current study aims to examine the impact of ICD on DLBCL and identify a corresponding gene signature in DLBC. Using the expression profiles of ICD-associated genes, the gene expression omnibus (GEO) samples were segregated into ICD-high and ICD-low subtypes utilizing non-negative matrix factorization clustering. Next, univariate and LASSO Cox regression analyses were employed to establish the ICD-related gene signature. Subsequently, the CIBERSORT tool, ssGSEA, and ESTIMATE algorithm were utilized to examine the association between the signature and tumor immune microenvironment of DLBC. Finally, the oncoPredict algorithm was implemented to evaluate the drug sensitivity prediction of DLBCL patients. These findings suggest that the immune microenvironment of the ICD-high group with a poor prognosis was significantly suppressed. An 8-gene ICD-related signature was identified and validated to prognosticate and evaluate the tumor immune microenvironment in DLBCL. Similarly, the high-risk group exhibited a worse prognosis compared to the low-risk group, and the immune function was considerably suppressed. Moreover, the results of oncoPredict algorithm indicated that patients in the high-risk group exhibited higher sensitivity to Cisplatin, Cytarabine, Epirubicin, Oxaliplatin, and Vincristine with low IC50. In conclusion, the present study provides novel insights into the role of ICD in DLBCL by identifying a new biomarker for the disease and may have implications for the development of immune-targeted therapies for the tumor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.420, Fuma Road, Fuzhou, Fujian, China.
- Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No.420, Fuma Road, Fuzhou, Fujian, China. LinYang@fjzlhospital.com.
Förderung
- Fujian Provincial Health Technology Project
- Natural Science Foundation of Fujian Province
- Joint Funds for the Innovation of Science and Technology, Fujian Province
Zitieren
APA
Huang, S., Liu, W., Zhao, Q., Chen, T., Huang, R., Dong, L., Nian, Z., & Yang, L. (2025). Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma. Biochemical Genetics. https://doi.org/10.1007/s10528-024-10697-6
Vancouver
Huang S, Liu W, Zhao Q, Chen T, Huang R, Dong L, et al. Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma. Biochemical Genetics. 2025. doi:10.1007/s10528-024-10697-6
BibTeX
@article{Huang2025,
author = {Huang, Shengqiang and Liu, Wenbin and Zhao, Qiuling and Chen, Ting and Huang, Ruyi and Dong, Liangliang and Nian, Zilin and Yang, Lin},
title = {Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma},
journal = {Biochemical Genetics},
year = {2025},
doi = {10.1007/s10528-024-10697-6}
}
EUVIMED